With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.
Add 4-(4,6-dimethoxy- 1,3 ,5-triazin-2-yl)-4-methylmorpholinium chloride (26.34 g, 94.86 mmol) to solution of 2-tert-butoxycarbonyl-3 ,4-dihydro- 1H-isoquinoline-6- carboxylic acid (18.79 g, 67.76 mmol), N,O-dimethylhydroxylamine hydrochloride (7.93g, 81.31 mmol) and N-methylmorpholine (13.71 g, 14.95 mL, 135.51 mmol) in methanol (563.70 mL). Stir the mixture at room temperature overnight. Concentrate under reduced pressure. Then add ethyl acetate (250 mL) and water (250 mL) to the mixture. Separate the layers and extract the aqueous layer with ethyl acetate (150 mL). Combine the organic layers, wash with aqueous hydrochloric acid solution (2 M, 200 mL), wash withsaturated aqueous sodium chloride (200 mL) and dry over sodium sulfate. Concentrate under reduced pressure to afford the title compound (24.28 g, 75.78 mmol). MS (m/z):321 (M+1).
170097-67-3, As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.
Reference£º
Patent; ELI LILLY AND COMPANY; BURKHOLDER, Timothy Paul; DEL PRADO, Miriam Filadelfa; FERNANDEZ, Maria Carmen; HEINZ II, Lawrence Joseph; PRIETO, Lourdes; ZHAO, Genshi; WO2015/54060; (2015); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem